Mural Oncology plc
MURADelisted Dec 5, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001971543
Mural Oncology plc was delisted on Dec 5, 2025; its insiders filed their last Form 4 on Dec 5, 2025; 61 institutions reported holding it in 13F filings for Q3 2025, worth $11.0M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 61
- Q3 2025, −5 vs. previous quarter
- 13F value
- $11.0M
- Reported value at the end of Q3 2025
- Superinvestors holding
- 0
- At the end of Q3 2025
Superinvestors holding MURA, Q3 2025
No superinvestor reported holding MURA at the end of Q3 2025.
Latest insider trades
Open-market purchases and sales by Mural Oncology plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 10, 2025 (view filing) | Nov 3 | 7 daysLate | Cutler Adam D.Chief Financial Officer | SSale | −7.15K | $2.09 | −$14.9K | −6.7%99.3K after | 10b5-1 |
| Nov 10, 2025 (view filing) | Nov 10 | Same day | Goodman Vicki LChief Medical Officer | SSale | −5.04K | $2.08 | −$10.5K | −5.6%84.7K after | 10b5-1 |
| Jul 23, 2025 (view filing) | Jul 22 | 1 day | Keson-Brookes MaikenSee Remarks | SSale | −2.57K | $2.48 | −$6.38K | −3.6%68.8K after | 10b5-1 |
| Jul 22, 2025 (view filing) | Jul 18 | 4 days | Keson-Brookes MaikenSee Remarks | SSale | −2.16K | $2.48 | −$5.35K | −2.9%71.4K after | 10b5-1 |
| Jul 9, 2025 (view filing) | Jul 7 | 2 days | Loew CarolineChief Executive Officer | SSale | −12.5K | $2.43 | −$30.5K | −4.1%293.1K after | 10b5-1 |
| Mar 5, 2025 (view filing) | Mar 4-5 | 1 day | Keson-Brookes MaikenSee Remarks | SSale | −2.73K | $3.41 | −$9.31K | −3.6%73.6K after | 2 lots10b5-1 |
| Mar 5, 2025 (view filing) | Mar 4 | 1 day | Loew CarolineChief Executive Officer | SSale | −4.31K | $3.36 | −$14.5K | −1.4%305.6K after | 10b5-1 |
| Feb 25, 2025 (view filing) | Feb 24 | 1 day | Goodman Vicki LChief Medical Officer | SSale | −13.2K | $3.89 | −$51.3K | −19.4%54.8K after | 10b5-1 |
| Dec 26, 2024 (view filing) | Dec 23 | 3 days | Keson-Brookes MaikenSee Remarks | SSale | −2.56K | $3.27 | −$8.35K | −5.8%41.3K after | 10b5-1 |
| Dec 18, 2024 (view filing) | Dec 17 | 1 day | Loew CarolineChief Executive Officer | SSale | −2.76K | $3.40 | −$9.39K | −1.1%237.6K after | 10b5-1 |
Top 10 13F holders, Q3 2025
The largest institutional positions in Mural Oncology plc at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 588,800 | $1.22M | 0.03% | 00.0% | Unchanged |
| Newtyn Management, LLC | 522,919 | $1.08M | 0.13% | −47,081−8.3% | Reduced |
| Omers Administration Corp | 511,000 | $1.06M | 0.01% | +511,000 | New |
| Vanguard Group Inc | 454,712 | $941.3K | 0.00% | −318,139−41.2% | Reduced |
| Rangeley Capital, LLC | 305,000 | $631.4K | 0.59% | +258,487+555.7% | Added |
| BlackRock, Inc. | 287,580 | $595.3K | 0.00% | +1,179+0.4% | Added |
| RBF Capital, LLC | 283,912 | $587.7K | 0.03% | 00.0% | Unchanged |
| Millennium Management LLC | 258,487 | $535.1K | 0.00% | −57,553−18.2% | Reduced |
| Citadel Advisors LLC | 258,250 | $534.6K | 0.00% | +185,898+256.9% | Added |
| Deltec Asset Management LLC | 179,057 | $370.6K | 0.06% | +179,057 | New |
Holders of 5% or more of MURA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Mural Oncology plc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Acorn Bioventures, L.P. | 13G/A | 7.60%1.29M shares | +1.30 ppfrom 6.30% | Aug 13, 20243 filings | Feb 14, 2025 | SEC |